Eli Lilly Plans Another Study for Alzheimer's Drug

Pharmaceutical giant Eli Lilly (NYSE: LLY  ) announced in a press release today that it will launch an additional phase 3 trial for its solanezumab treatment for patients with mild Alzheimer's disease. The company said it plans to begin the study no later than the third quarter of next year.

Eli Lilly doesn't believe it has sufficient results to gain regulatory clearance after the company met with the FDA, as well as Canadian and European regulators.  But Eli Lilly'spresident of bio-medicines, David Ricks, said in the release that "We remain encouraged and excited by the solanezumab data."

Still, another trial will delay the potential launch of the drug should it clear regulatory hurdles, with a potential introduction possible by 2016 if the next study does indeed commence next year. Eli Lilly will continue to review the data and results from its earlier two phase 3 studies of solanezumab after the drug failed to meet its primary endpoints in those trials.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2150743, ~/Articles/ArticleHandler.aspx, 7/31/2014 2:32:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement